Latest Content

Stage 3 ccRCC is locally advanced but often treatable. Learn how it is diagnosed, treated, and managed to support informed decisions with your care team.

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

I never thought about mantras until my diagnosis with colon cancer at the age of 34.

Dr. Maral Kibarian Skelsey discussed how advances in genetics and genomics are reshaping the understanding of skin cancer risk and prevention.

Dr. Jesse Miller Lewin sat down with CURE to discuss how advances in systemic and local therapies are reshaping the treatment landscape for skin cancer.

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.

The FDA has granted orphan drug designation to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.

FDA expands access to CAR-T cell therapy for patients with relapsed or refractory PCNSL.

Dr. Elias Obeid says ongoing monitoring after treatment helps detect recurrence early and identify late effects, supporting survivorship for patients.

Dr. Suneel Kamath emphasized the growing importance of understanding biomarkers in patients with gastrointestinal cancers.

Relacorilant plus Abraxane showed benefit without biomarker testing, potentially expanding treatment access for patients with platinum-resistant ovarian cancer.

Oral KTX-1001 achieved 40% disease control in phase 1 trials, offering a new targeted therapy for aggressive t(4;14) translocation multiple myeloma.

Relacorilant plus Abraxane improved overall survival by 4.1 months without added toxicity and no biomarker testing in ROSELLA.